ClinicalTrials.gg
Not yet recruitingNCT06846151Updated Feb 25, 2025

Retinal Investigation Using Optos OCT Device

An interventional study of retinal functional imaging in AMD - Age-Related Macular Degeneration, Retinitis Pigmentosa (RP) and Diabetic Retinopathy, sponsored by Optos, PLC. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-25.

Sponsored by Optos, PLC · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Retinal investigation using OCT with control and diseased eyes

02

Conditions studied

  • AMD - Age-Related Macular Degeneration
  • Retinitis Pigmentosa (RP)
  • Diabetic Retinopathy
  • Control Patients
03

In context

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

This study's planned enrollment of 120 is above the median of 56 across 986 interventional studies indexed under Macular Degeneration.

Browse Macular Degeneration studies →

Lead sponsor

Optos, PLC is the lead sponsor of 18 studies on the registry; 3 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants 18 years of age or older who have full legal capacity to volunteer on the date the is signed.
  2. Participants who understand the study and patient information sheet and can follow the instructions.
  3. Participants who agree to participate in the study.
  4. Control group where no retinal abnormalities were detected as part of the standard basic ophthalmic examination.
  5. Participants with retinal disease in at least one eye including: Early dry age-related macular degeneration, late stage dry age-related macular degeneration specifically geographic atrophy, Wet age-related macular degeneration, Retinitis pigmentosa, Diabetic retinopathy and other macular atrophic diseases

Exclusion criteria

Exclusion Criteria:

  1. Inability to understand written and verbal English sufficiently to comprehend the study and provide
  2. Ophthalmic disease other than condition under investigation.
  3. Participants unable to tolerate ophthalmic imaging.
  4. Cataract (unless deemed mild in the opinion of the investigator)
  5. Participants with significant ocular media not sufficiently clear to obtain acceptable OCT images.
  6. Diabetes (unless part of the diabetic eye disease group)
  7. Binocular visual acuity worse than 6/18
  8. Strabismus (squint)
  9. Age related macular degeneration groups: polypoidal choroidal vasculopathy
  10. Participants with photo sensitivity epilepsy, experience of seizures, or sensitivity to flickering light (based on self-report)
  11. Pregnant
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Other
    standard imaging process

    All participants will undergo the same imaging

    Device: retinal functional imaging

Interventions

  • Deviceretinal functional imaging

    this is a proof of concept study

    Also known as: OCT

06

What researchers measure

Primary outcomes

  1. OCT physical response data

    Response data per participant will be collected and analyzed

    Time frame: 6 months from recruitment start

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2025; primary completion for Nov 2025, 6 months later.

Of 133 interventional studies with no phase under Macular Degeneration, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 60. This study's planned 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2025
First posted
Feb 25, 2025
StartEst.
May 2025
Primary completionEst.
Nov 2025
CompletionEst.
Jan 2026
Last update
Feb 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06846151
Lead sponsor
Optos, PLC
Responsible party
Sponsor
First posted
Feb 25, 2025
Start date
May 2025 (estimated)
Primary completion
Nov 2025 (estimated)
Completion
Jan 2026 (estimated)
Last update
Feb 25, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion